US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.21 against a street estimate of 0.28 — a miss of 25.0%.
Analysts rate Supernus Pharmaceuticals Inc a buy (2 buy, 3 hold, 0 sell out of 5) with an average price target of $63.50.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.16% |
| Millennium Management LLC | 5.71% |
| Vanguard Portfolio Management, LLC | 5.58% |
| Vanguard Capital Management, LLC | 4.25% |
| Dimensional Fund Advisors, Inc. | 3.97% |
| State Street Corp | 3.94% |
| Delaware Management Holdings Inc | 3.51% |
| Armistice Capital, LLC | 3.27% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 | 2026-08-03 |
| Quarterly report · Q2 2026 | 2026-08-03 |
| Results announced · Q3 2026 | 2026-08-03 |
| Material agreement · Q3 2026 | 2026-08-03 |
| Results announced · Q3 2026 | 2026-07-22 |
| Quarterly report · Q1 2026 | 2026-05-05 |
| Proxy statement · Q2 2026 | 2026-04-30 |
| Annual report FY2025 | 2026-03-02 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Supernus Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.